Explore homologous recombination deficiency (HRD) evaluation and scoring using the OncoScan CNV Assay in this informative webinar presented by Yann Christinat, PhD and Stephan Bartels, PhD. Learn about this whole-genome microarray research solution and its applications in identifying HRD as a genome-wide biomarker in high-grade ovarian and breast cancers. Discover how PARP inhibitors, a cancer therapeutic class, induce synthetic lethality in tumors with high levels of HRD. Gain valuable insights into the latest advancements in cancer research and potential therapeutic approaches during this 1-hour and 4-minute presentation.